Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016–2020. Neuro Oncol 25:iv1–iv99. https://doi.org/10.1093/neuonc/noad149

Article  PubMed  PubMed Central  Google Scholar 

Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Debus J, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas–clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 83:859–864. https://doi.org/10.1016/j.ijrobp.2011.08.010

Article  PubMed  Google Scholar 

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211–217. https://doi.org/10.1007/s11060-009-9948-7

Article  CAS  PubMed  Google Scholar 

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109:187–193. https://doi.org/10.1007/s11060-012-0886-4

Article  CAS  PubMed  Google Scholar 

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honore S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 26:552–557. https://doi.org/10.1158/1078-0432.CCR-19-2109

Article  CAS  PubMed  Google Scholar 

Belanger K, Ung TH, Damek D, Lillehei KO, Ormond DR (2022) Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. BMC Cancer 22:367. https://doi.org/10.1186/s12885-022-09340-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutaions in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark VE, Harmanci AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrion-Grant G, Mishra-Gorur K, Duran D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Gunel JM, Bilguvar K, Yasuno K, Young RA, Gunel M (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259. https://doi.org/10.1038/ng.3651

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okano A, Miyawaki S, Teranishi Y, Ohara K, Hongo H, Sakai Y, Ishigami D, Nakatomi H, Saito N (2022) Advances in molecular biological and translational studies in world health organization grades 2 and 3 meningiomas: A literature review. Neurologia medico-chirurgica 62:347–360. https://doi.org/10.2176/jns-nmc.2022-0114

Article  PubMed  PubMed Central  Google Scholar 

Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H (2002) Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6:219–226. https://doi.org/10.1006/mthe.2002.0647

Article  CAS  PubMed  Google Scholar 

Gupta A, Andresen JL, Manan RS, Langer R (2021) Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev 178:113834. https://doi.org/10.1016/j.addr.2021.113834

Article  CAS  PubMed  Google Scholar 

Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124:2478–2487. https://doi.org/10.1002/ijc.24234

Article  CAS  PubMed  Google Scholar 

Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y (2012) TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18:6271–6283. https://doi.org/10.1158/1078-0432.CCR-12-1595

Article  CAS  PubMed  Google Scholar 

Shi LY, Han Z, Li XX, Li M, Han H, Chen J, Zang S (2015) Inactivated Sendai virus strain Tianjin induces apoptosis in breast cancer MCF-7 cells by promoting caspase activation and fas/fasl expression. Cancer Biother Radiopharm 30:33–40. https://doi.org/10.1089/cbr.2014.1704

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y (2005) Rad51 SiRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7:1044–1052. https://doi.org/10.1002/jgm.753

Article  CAS  PubMed  Google Scholar 

Kiyohara E, Tamai K, Katayama I, Kaneda Y (2012) The combination of chemotherapy with HVJ-E containing Rad51 SiRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 19:734–741. https://doi.org/10.1038/gt.2011.123

Article  CAS  PubMed  Google Scholar 

Matsuda M, Yamamoto T, Matsumura A, Kaneda Y (2009) Highly efficient eradication of intracranial glioblastoma using Eg5 SiRNA combined with HVJ envelope. Gene Ther 16:1465–1476. https://doi.org/10.1038/gt.2009.99

Article  CAS  PubMed  Google Scholar 

Matsuda M, Nimura K, Shimbo T, Hamasaki T, Yamamoto T, Matsumura A, Kaneda Y (2011) Immunogene therapy using Immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J Neurooncol 103:19–31. https://doi.org/10.1007/s11060-010-0355-x

Article  CAS  PubMed  Google Scholar 

Sugii N, Matsuda M, Okumura G, Shibuya A, Ishikawa E, Kaneda Y, Matsumura A (2021) Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 SiRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Cancer Sci 112:81–90. https://doi.org/10.1111/cas.14721

Article  CAS  PubMed  Google Scholar 

Lu TX, Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141:1202–1207. https://doi.org/10.1016/j.jaci.2017.08.034

Article  CAS  PubMed  Google Scholar 

Slavik H, Balik V, Vrbkova J, Rehulkova A, Vaverka M, Hrabalek L, Ehrmann J, Vidlarova M, Gurska S, Hajduch M, Srovnal J (2020) Identification of meningioma patients at high risk of tumor recurrence using MicroRNA profiling. Neurosurgery 87:1055–1063. https://doi.org/10.1093/neuros/nyaa009

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Zhang G, Huang H, Li H, Lin S, Wang Y (2020) Differentially expressed MicroRNAs in radioresistant and radiosensitive atypical meningioma: A clinical study in Chinese patients. Front Oncol 10:501. https://doi.org/10.3389/fonc.2020.00501

Article  PubMed  PubMed Central  Google Scholar 

Li S, Wei X, He J, Cao Q, Du D, Zhan X, Zeng Y, Yuan S, Sun L (2021) The comprehensive landscape of miR-34a in cancer research. Cancer Metastasis Rev 40:925–948. https://doi.org/10.1007/s10555-021-09973-3

Article  CAS  PubMed  Google Scholar 

Werner TV (2017) MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging 9:932–954. https://doi.org/10.18632/aging.101201

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H, Wood WC (2004) Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 11:1215–1223. https://doi.org/10.1038/sj.gt.3302280

Article  CAS  PubMed  PubMed Central